

Tavalisse™ (fostamatinib) (Oral)

Document Number: IC-0361

Last Review Date: 02/01/2022

Date of Origin: 06/01/2018

Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021, 02/2022

I. Length of Authorization

Coverage is provided for three months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Tavalisse 100 mg tablets: 2 tablets per day
- Tavalisse 150 mg tablets: 2 tablets per day

B. Max Units (per dose and over time) [HCPCS Unit]:

- 300 mg daily

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); **AND**
- Laboratory values for platelet count are current (i.e., drawn within the previous 28 days); **AND**
- Fostamatinib is not being used to attempt to normalize platelet count; **AND**
- Patient will avoid concomitant therapy with all of the following:
 - Coadministration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented; **AND**
 - Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort, etc.); **AND**

Chronic Immune Thrombocytopenia (ITP) † Φ 1,2

- Patient has had persistent/chronic ITP for at least 3 months; **AND**
- Patient has previously failed any of the following treatments for ITP:
 - Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); **OR**
 - Patient has failed previous therapy with immunoglobulins; **OR**
 - Patient has had a splenectomy; **OR**
 - Patient has failed previous therapy with a thrombopoietin receptor agonist (romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); **AND**
- The patient is at increased risk for bleeding as indicated by platelet count of less than $30 \times 10^9/L$ ($30,000/mm^3$)

† FDA Approved Indication(s); ‡ Compendia recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria ¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hepatotoxicity (elevated liver function tests), hypertension, severe diarrhea, severe neutropenia, etc.; **AND**
- Disease response as indicated by the achievement and maintenance of a platelet count of at least $50 \times 10^9/L$ as necessary to reduce the risk of bleeding

V. Dosage/Administration ¹

Indication	Dose
Chronic ITP	<ul style="list-style-type: none">• Initiate at a dose of 100 mg orally twice daily.• After 4 weeks, if platelet count has not increased to at least $50 \times 10^9/L$, increase dose to 150 mg twice daily.

VI. Billing Code/Availability Information

HCPCS code:

- J8499 – Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified

NDC:

- Tavalisse 100 mg tablets: 71332-0001-xx
- Tavalisse 150 mg tablets: 71332-0002-xx

TAVALISSE™ (fostamatinib disodium hexahydrate)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2022, Magellan Rx Management

VII. References

1. Tavalisse [package insert]. San Francisco, CA; Rigel Pharmaceuticals; November 2020. Accessed January 2022.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv.* 2019 Dec 10;3(23):3829-3866.
3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood.* 2017. 129:2829-2835. Doi:10.1182/blood-2017-03-754119.
4. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol.* 2018. Doi: 10.1002/ajh.25125.
5. Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. *Am J Hematol.* 2019 May;94(5):546-553.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D69.3	Immune thrombocytopenic purpura

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs), and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC

TAVALISSE™ (fostamatinib disodium hexahydrate)
Prior Auth Criteria

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC